MISSION Therapeutics Company

Mission Therapeutics is a drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylatingenzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.
Technology: Cancer
Industry: Mitochondrial Dynamics
Headquarters: United Kingdom
Founded Date: 2011
Employees Number: 11-50
Funding Status: Late Stage Venture
Estimated Revenue: $10M to $50M

Visit Website
info@missiontherapeutics.com
http://twitter.com/MISSIONTherapeu
Register and Claim Ownership